Ribozyme Pharmaceuticals acquired rights to Heptazyme from Eli Lilly and Company. Heptazyme cleaves the HCV genetic material precisely in a highly conserved region. This prevents replication. Such advances should further enhance the effectiveness of management. In other words, viral load monitoring in HIV and HCV offers the opportunity to tailor expensive treatments to those patients most likely to respond.
Monitoring allows clinicians to stay on top of changes in viral mutation.
And integrated management supports the launch of new medications. Finally, integrated management's ability to improve clinical and cost effectiveness may offer a paradigm of future approaches to the treatment of other viral diseases. To respond to this article, click here . Responses will be posted at the bottom of this page. You can respond to features by using the facility at the bottom of every article.